AdipoGen Life Sciences

Cagrilintide. AcOH - Research Use Only

Product Code:
 
AG-CP3-0047
Product Group:
 
Peptides
Regulatory Status:
 
RUO
Shipping:
 
Ambient
Storage:
 
Short term: +4°C. Long term: -20°C
1 / 1
Chemical Structure

Chemical Structure

No additional charges, what you see is what you pay! *

CodeSizePrice
AG-CP3-0047-M0011 mg£81.00
Quantity:
AG-CP3-0047-M0055 mg£221.00
Quantity:
AG-CP3-0047-M02525 mg£641.00
Quantity:
Prices exclude any Taxes / VAT
Stay in control of your spending. These prices have no additional charges to UK mainland customers, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: Switzerland.
Typical lead time: 7-10 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • Show All

Further Information

Appearance:
White powder.
CAS:
1415456-99-3 (free acid)
Endotoxin:
< 10EU/mg
Form:
solid
Handling Advice:
Keep cool and dry.
InChi:
InChI=1S/C194H312N54O59S2.C2H4O2/c1-19-100(10)151(184(298)233-128(78-98(6)7)189(303)248-75-49-60-137(248)190(304)247-74-48-59-136(247)182(296)243-155(107(17)255)187(301)232-127(86-143(201)262)173(287)238-150(99(8)9)183(297)210-88-146(265)218-129(90-249)176(290)230-126(85-142(200)261)175(289)244-156(108(18)256)191(305)246-73-46-57-134(246)157(202)271)239-181(295)135-58-47-72-245(135)147(266)89-211-161(275)120(79-109-50-36-34-37-51-109)225-171(285)123(82-139(197)258)228-172(286)124(83-140(198)259)229-177(291)130(91-250)235-178(292)131(92-251)234-170(284)122(81-111-87-207-95-212-111)227-164(278)114(56-45-71-209-194(205)206)221-168(282)119(77-97(4)5)224-169(283)121(80-110-52-38-35-39-53-110)226-166(280)116(65-68-149(269)270)219-158(272)101(11)213-167(281)118(76-96(2)3)223-163(277)113(55-44-70-208-193(203)204)220-165(279)115(63-66-138(196)257)222-186(300)153(105(15)253)240-159(273)102(12)214-179(293)132-93-308-309-94-133(180(294)231-125(84-141(199)260)174(288)242-152(104(14)252)185(299)215-103(13)160(274)241-154(106(16)254)188(302)237-132)236-162(276)112(54-42-43-69-195)216-145(264)67-64-117(192(306)307)217-144(263)61-40-32-30-28-26-24-22-20-21-23-25-27-29-31-33-41-62-148(267)268;1-2(3)4/h34-39,50-53,87,95-108,112-137,150-156,249-256H,19-33,40-49,54-86,88-94,195H2,1-18H3,(H2,196,257)(H2,197,258)(H2,198,259)(H2,199,260)(H2,200,261)(H2,201,262)(H2,202,271)(H,207,212)(H,210,297)(H,211,275)(H,213,281)(H,214,293)(H,215,299)(H,216,264)(H,217,263)(H,218,265)(H,219,272)(H,220,279)(H,221,282)(H,222,300)(H,223,277)(H,224,283)(H,225,285)(H,226,280)(H,227,278)(H,228,286)(H,229,291)(H,230,290)(H,231,294)(H,232,301)(H,233,298)(H,234,284)(H,235,292)(H,236,276)(H,237,302)(H,238,287)(H,239,295)(H,240,273)(H,241,274)(H,242,288)(H,243,296)(H,244,289)(H,267,268)(H,269,270)(H,306,307)(H4,203,204,208)(H4,205,206,209);1H3,(H,3,4)/p-1/t100-,101-,102-,103-,104+,105+,106+,107+,108+,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,150-,151-,152-,153-,154-,155-,156-;/m0./s1
InChiKey:
ZVFSCEVVTIADGE-SXJCWIKGSA-M
Long Description:
Chemical. CAS: 1415456-99-3 (free acid). Formula: C194H312N54O59S2 . C2H4O2. MW: 4409.0 . 60.0. Soluble in water (50mg/ml). Cagrilintide is a novel long-acting nonselective amylin receptors (AMYR) and calcitonin G protein-coupled receptor (CTR) agonist. Cagrilintide is a stable synthetic peptide acylated amylin analog. Natural amylin is a pancreatic hormone that induces satiety. Cagrilintide binds human, mouse and rat amylin receptors and is used in studies of obesity and type 2 diabetes (T2D) and is designed enhancing energy expenditure and fat metabolism and decreasing food intake. Cagrilintide is now being developed in combination with the GLP-1 agonist semaglutide as "CagriSema" to achieve sustained weight loss in persons with overweight and obesity. Amylin, released with insulin from beta cells in the pancreas, induces its satiating effect via both the homoeostatic and hedonic regions of the brain. Semaglutide, a GLP-1 receptor agonist, reduces appetite via GLP-1 receptors in the hypothalamus and increases the production of insulin, and reduces glucagon secretion, delaying gastric emptying. These separate, but related mechanisms of action of an amylin-analog and a GLP-1 receptor agonist appear to have an additive effect on appetite reduction. Cagrilintide comprises a 37 amino acid linear synthetic peptide conjugated to a C20 fatty diacid through a hydrophilic linker at the lysine residue at position 1. Due to this moiety, the compound is highly bound to albumin in the plasma which prolongs its half-life. The N-terminus of the amylin peptide is predicted to form a loop, stabilized by a disulfide bond, that points out of the TM area, thereby tolerating N-terminal lipidation.
Molecular Formula:
C194H312N54O59S2 . C2H4O2
Molecular Weight:
4409.0 . 60.0
Package Type:
Vial
Product Description:
Cagrilintide is a novel long-acting nonselective amylin receptors (AMYR) and calcitonin G protein-coupled receptor (CTR) agonist. Cagrilintide is a stable synthetic peptide acylated amylin analog. Natural amylin is a pancreatic hormone that induces satiety. Cagrilintide binds human, mouse and rat amylin receptors and is used in studies of obesity and type 2 diabetes (T2D) and is designed enhancing energy expenditure and fat metabolism and decreasing food intake. Cagrilintide is now being developed in combination with the GLP-1 agonist semaglutide as "CagriSema" to achieve sustained weight loss in persons with overweight and obesity. Amylin, released with insulin from beta cells in the pancreas, induces its satiating effect via both the homoeostatic and hedonic regions of the brain. Semaglutide, a GLP-1 receptor agonist, reduces appetite via GLP-1 receptors in the hypothalamus and increases the production of insulin, and reduces glucagon secretion, delaying gastric emptying. These separate, but related mechanisms of action of an amylin-analog and a GLP-1 receptor agonist appear to have an additive effect on appetite reduction. Cagrilintide comprises a 37 amino acid linear synthetic peptide conjugated to a C20 fatty diacid through a hydrophilic linker at the lysine residue at position 1. Due to this moiety, the compound is highly bound to albumin in the plasma which prolongs its half-life. The N-terminus of the amylin peptide is predicted to form a loop, stabilized by a disulfide bond, that points out of the TM area, thereby tolerating N-terminal lipidation.
Purity:
>98% (HPLC)
Sequence:
{Eicosanedioic acid-gamma-Glu}-Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Glu-Phe-Leu-Arg-His-Ser-Ser-Asn-Asn-Phe-Gly-Pro-Ile-Leu-Pro-Pro-Thr-Asn-Val-Gly-Ser-Asn-Thr-Pro-NH2 (Disulfide bridge:Cys2-Cys7)
SMILES:
O=C(N)[C@H]1N(C([C@H]([C@H](O)C)NC([C@H](CC(N)=O)NC([C@H](CO)NC(CNC([C@H](C(C)C)NC([C@H](CC(N)=O)NC([C@H]([C@H](O)C)NC([C@H]2N(C([C@H]3N(C([C@H](CC(C)C)NC([C@H]([C@@H](C)CC)NC([C@H]4N(C(CNC([C@H](CC5=CC=CC=C5)NC([C@H](CC(N)=O)NC([C@H](CC(N)=O)NC([C@H](CO)NC([C@H](CO)NC([C@H](CC6=CNC=N6)NC([C@H](CCCNC(N)=N)NC([C@H](CC(C)C)NC([C@H](CC7=CC=CC=C7)NC([C@H](CCC(O)=O)NC([C@H](C)NC([C@H](CC(C)C)NC([C@H](CCCNC(N)=N)NC([C@H](CCC(N)=O)NC([C@H]([C@H](O)C)NC([C@H](C)NC([C@H](CSSC[C@@H]8NC([C@H](CCCCN)NC(CC[C@@H](C(O)=O)NC(CCCCCCCCCCCCCCCCCCC(O)=O)=O)=O)=O)NC([C@H]([C@H](O)C)NC([C@H](C)NC([C@H]([C@H](O)C)NC([C@H](CC(N)=O)NC8=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)CCC4)=O)=O)=O)CCC3)=O)CCC2)=O)=O)=O)=O)=O)=O)=O)=O)CCC1.CC([O-])=O
Solubility Chemicals:
Soluble in water (50mg/ml).
Transportation:
Non-hazardous
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 1 year after receipt when stored at -20°C.

Documents